Merck and Ridgeback's Molnupiravir, an Oral COVID-19 Antiviral Medicine, Receives First Authorization in the World Pharmaceutical Investing
INVESTOR ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Class Action Lawsuits filed on behalf of BMY, EAR, HYZN, WDH Investors, Lead Plaintiff Deadlines Set Pharmaceutical Investing
BRISTOL MYERS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Bristol-Myers Squibb Company - BMY Pharmaceutical Investing
Abbott Launches New Initiative to Drive Diversity in Medical Research and Improve Care Among Under-Represented Populations Pharmaceutical Investing
Bristol Myers Squibb Data at ACR Convergence 2021 Illustrate Scientific Advances for Immune-Mediated Rheumatic Diseases Pharmaceutical Investing
Aurinia Reports Third Quarter and Nine Months 2021 Financial Results and Company Updates Pharmaceutical Investing
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of BMY, HNST and HYZN Pharmaceutical Investing
Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Units Pharmaceutical Investing
OPDIVO® Receives Two New Health Canada Approvals for: Use with Chemotherapy for the Treatment for Patients with HER2 Negative Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenocarcinoma Cancers; Use as Monotherapy for the Adjuvant Treatment for Patients with Completely Resected Esophageal or Gastroesophageal Junction Cancers Pharmaceutical Investing
